We are always evolving in an ever-changing industry.

Keep up-to-date with PrECOG by visiting our news page regularly.

Official BRACELET-1 trial results indicate that adding the oncolytic virus immunotherapy pelareorep to paclitaxel chemotherapy warrants further investigation in HR+ HER2- metastatic breast cancer

Clinical Cancer Research has published a report detailing the safety and efficacy of pelareorep combined with paclitaxel chemotherapy, with or without the checkpoint inhibitor avelumab, for patients whose disease progressed after first-line treatment The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the safety and efficacy of […]

Venetoclax with standard chemo-immunotherapy induced a high response rate as first-line treatment for mantle cell lymphoma and was generally well tolerated, a PrECOG early-phase trial shows

Trial PrE0405 met its primary endpoint. Venetoclax combined with bendamustine+rituximab as the first therapy for MCL in patients over age 60 led to a complete response rate of 85%. The American Society of Hematology 2023 annual meeting featured the data. The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate […]

ECOG-ACRIN and PrECOG announce multiple presentations at ASH 2023

Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present six oral and three poster presentations at the 65th American Society of Hematology Meeting & Exposition, occurring in San Diego, California and virtually December 9 – 12, 2023. The presentations focus on treatments for acute leukemias and lymphoma. Among the data are […]

PrECOG investigators present trial updates and new data at ASCO 2023

PALLAS co-chair Angela DeMichele receives the 2023 Gianni Bonadonna Breast Cancer Award Researchers with PrECOG, LLC, are presenting updates and new data at the 2023 annual meeting of the American Society of Clinical Oncology (ASCO), occurring in Chicago and online during the first weekend in June. Below, please find the essential information for the presentations, […]

Nature Medicine publishes phase 2 trial data showing durvalumab immunotherapy with standard chemotherapy improved survival in malignant pleural mesothelioma

In-depth molecular analyses of responding tumors provide insights into patient selection methods for this novel chemo-immunotherapy regimen, which is currently being evaluated in the DREAM3R phase 3 trial, open to patients in the US, Australia, and New Zealand Philadelphia, November 8, 2021—The PrE0505 phase 2 clinical trial results are published in the November 8 issue […]